Professional Documents
Culture Documents
If we are to afford new drugs, we must make trials cheaper and quicker
Research environment
New treatments usually not better than current
About 30 to 40% are positive Both academia and industry
C Phase II
T1
T2 T3 T4
Clinical Setting
Men with metastatic or high-risk non-metastatic prostate cancer Long-term hormone therapy (HT) alone is the standard of care Investigating whether early use of additional therapies can improve overall survival Many interesting agents demand assessment
No clear reason to choose one particular regimen Do not want to choose arbitrarily Want to assess all interesting agents
Pilot
Activity I-III (phase II)
Safety
Failure-free survival
Feasibility
Overall survival Toxicity / safety Skeletal events
Overall survival
STAMPEDE trial
Launched 2005 Initial feasibility stage:
Would patients accept randomisation between 6 treatment arms? Would clinicians put the time into the study to make it work? Would the chosen treatments be safe?
RANDOMISATION
B ADT + Zoledronic Acid C ADT + Docetaxel D ADT + Celecoxib E ADT + ZA + Doc F ADT + ZA + Cel
Docetaxel :: Taxane chemotherapy :: IV for 6 cycles over 18 weeks Celecoxib :: Cox-2 inhibitor :: Oral MRC for 1 PR08 year
CRUK/06/019 ISRCTN78818544
NCT00268476
2005 A B C D E F
2006
2007
2008
2009
Accrual: start
2010 2011 2012 2013
2014
2015
2016
2017
Follow-up
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 A B C D E F ADT-alone ADT + zoledronic acid ADT + docetaxel ADT + celecoxib
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 A B C D E F ADT-alone ADT + zoledronic acid ADT + docetaxel ADT + celecoxib
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 A B C D E F ADT-alone ADT + zoledronic acid ADT + docetaxel ADT + celecoxib
Follow-up
Might see as a new trial within STAMPEDE protocol Must be scientifically compelling case for inclusion
Proposed through Trial Management Group Survey of participants Peer review through original funder (Cancer Research UK)
Advantages?
1. Can start recruiting quicker than a new trial
Updated protocol = simple, substantial amendment Scientific review = amendment
R A N D O M I S E
E C B
Control
Con trol a r m
HT + zoledronic acid
HT + docetaxel
HT + G abiraterone
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 A B C D E F G ADT-alone ADT + zoledronic acid ADT + docetaxel ADT + celecoxib
Follow-up
0.8
New arm switched on for whole trial on set date Sites given ~4 wk notice to gain local approvals 80 sites ready to recruit on activation day!
Activation day
0.6
0.4
0.2
0.0 0
Sites needing approval
104 (6) 98 (21) 77 (19) 58 (11) 47 (26) 21 (8) 13 (0) 13 (1) 12 (1) 11 (4) 7 (0) 7 (0) 7 (0) 7 (1) 6 (3) 3
Aug 13
O ct 05 Jan 06
J ul 06
Jan 07
J ul 07
Jan 08
J ul 08
Jan 09
J ul 09
Jan 10
J ul 10
Jan 11
J ul 11
Jan 12
J ul 12
Jan 13
Z:\Prostate\Stampede\Data\Accrual\rand_planned.wmf
1200
900
600
O ct 13
Apr 13
300
0
J an 12 J ul 12 J an 13 J ul 13 J an 14 J ul 14 J an 15
D ate of r andomisation
Z:\Prostate\Stampede\Data\Accrual\abi_comparison_accrual.wmf
J ul 13
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 A B C D E F G H
Past accrual Possible future accrual
Docetaxel and Zoledronic Acid pass their final high jump round
Future arms
Abiraterone + Enzalutamide
Set to open Spring 2014
Radium-223 Metformin
Analysis: ZA comparison
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 A B C D E F G H M1 only
In analysis Not in analysis
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 A B C D E F G H M1 only
In analysis Not in analysis
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 A B C D E F G H M1 only
In analysis Not in analysis
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 A B C D E F G H M1 only
In analysis Not in analysis
0.75
Proportion event-free
0.75
0.50
0.50
0.25
0.25
12
24
36
48
Bone only
20 Lowest 20 2 20 3 20 4 20 Highest
43 (32, 54)
38 (27, 48) 30 (19, 40) 23 (14, 33) 21 (12, 30)
1.00 1.06 (0.74, 1.52) 1.30 (0.92, 1.85) 1.57 (1.11, 2.22) 1.94 (1.39, 2.72)
73 (61, 82)
69 (57, 79) 71 (59, 80) 75 (63, 83) 66 (54, 76)
1.00 0.80 (0.48, 1.32) 0.97 (0.60, 1.56) 0.94 (0.58, 1.51) 1.27 (0.80, 2.02)
481 201
71 29
Under 70 70 or over
0.50
0.50
0.25
0.25
12
24
36
48
W HO PS 0
W HO PS 1&2
0.75
0.75
0.50
0.50
0.25
0.25
Time from randomisation (Months) <4 363 4+ 201 233 112 124 45 73 16 24 3
<4
4+
36 10 16 18 22
Abiraterone
44 59 63 72
Bisphosphonate
Failure-free and overall survival for newlydiagnosed M1 patients in the STAMPEDE trial
Conclusions
Metastatic patients are castration resistant for the majority of the disease course Performance status, PSA nadir and metastatic site are highly prognostic Age, PSA and Gleason score at diagnosis were not prognostic Overall survival is longer than in older series
Study authors
James, Nicholas David Clarke, Noel W Mason, Malcolm David Dearnaley, David Paul De Bono, Johann Parker, Christopher Parmar, Mahesh Ritchie, Alastair SW Russell, J. Martin Spears, Melissa R Thalmann, George Sydes, Matthew Robert On behalf of the STAMPEDE Investigators